Otto Balsiger

Join sector leaders from industry, academia & the clinic at the BSI Immune Therapies Summit 🧬

📅 18–19 May 2026 | 📍 Cambridge, UK

Two days of cutting-edge science, networking & discussion shaping the future of immune therapies.

Learn more: https://bit.ly/3LW5uNc

Registration is now open for the Oxford Immunology Symposium 2026! #OIS26

Join us on Wed 1 April at the Mathematical Institute, University of Oxford, for a one day showcase of immunology research across Oxford.

Register now & submit an abstract here: https://bit.ly/4qUY8bD

Really looking forward to speaking (for the 3rd year!) at the British Society for Immunology (@britsocimm.bsky.social) Foundations of Immunology course on 18 March 🧬

A brilliant one-day online course covering core immunology for all backgrounds 🧪

Register 👉 www.immunology.org/training/Fou...

If you get the chance do come to this meeting if promises to he a great one..

Low MHC‑I expression remains a major barrier to effective tumour immunotherapy, especially in paediatric cancers.

This review outlines mechanisms of MHC‑I downregulation and emerging approaches to restore antigen presentation.

📄 https://bit.ly/45vtfmp

Type‑17 immunity shows up in the gut: axSpA stool contains increased IL‑17A, IL‑23 & GM‑CSF, alongside systemic Th17 activation.

Metabolomics points to microbial metabolic links.

Read here: https://bit.ly/4nkhC7q

MOG/NMDAR overlapping syndrome is increasingly recognised.

This review shows common symptoms (psychiatric changes, seizures), typical MRI patterns, good treatment response, but a notably higher recurrence rate.

Read here📄 https://bit.ly/3Q2S29A

Can’t wait for this one..

Want to take your omic data analysis to the next level?

Our advanced R course for wet lab immunologists starts on 2 February 2026, with five online Monday sessions covering statistics, clinical data, RNA seq and proteomics.

Register now 👉 https://bit.ly/47kXFaC

Despite elevated KLR and mitochondrial gene expression, Tregs in autoimmune PAI show normal frequency and suppressive function, suggesting limited involvement in disease pathogenesis.

📄 https://bit.ly/3Q2QVGU

How do human ILCs adapt to lung niches?

Single‑cell profiling shows distinct vascular vs. tissue programs and a shared extravascular “tissue signature” with NK cells.

Read here: https://bit.ly/4qiLJP6

Submissions now open for the Extracellular Vesicles & Immune Function topic—exosomes, microvesicles, immunomodulation, disease mechanisms & therapy.

Submit by May 2026: https://bit.ly/3YpmLRI

High‑throughput long‑read sequencing uncovers how chickens diversify their Ig genes: dominant somatic gene conversion, biased pseudogene usage, and focused CDR‑targeted insertions.

A look into avian antibody evolution: https://bit.ly/45wSe95

🚀 Submit your work to the Neuroimmunology & Immunotherapy Special Collection

Covering neurodegeneration, neuroinflammation, immune checkpoints, gut–brain axis, and more.

Deadline: March 2026.

Learn more: https://bit.ly/4psT5hG

Tumour‑reactive plasma cells are emerging as powerful players in cancer immunotherapy.

This review highlights their role, the promise of neoantigen‑reactive PCs, and the challenges in epitope prediction and screening.

📄 https://bit.ly/3SVZsMC

Working in immunology?

Clinical & Experimental Immunology publishes impactful studies across six core sections plus areas like immunometabolism, mucosal immunity, and immunotherapy.

Learn more about submitting your next manuscript to CEI: https://bit.ly/443pf8s

Important CIDP research shows significant changes in circulating B‑cell subsets and elevated IL10/TNFA expression, correlating with disability scores and nerve fiber density. Valuable insights for understanding disease activity.

📄 https://bit.ly/3rzemhN

This study highlights 2B4 (CD244) as a key receptor driving Staphylococcus aureus–associated allergic inflammation. SEB binds and activates 2B4, amplifying eosinophil responses, pointing to a promising therapeutic target.

📄 https://bit.ly/4my2B1e

Want to attend your next conference but need funding?💡

The BSI Conference Travel Grants can cover your travel costs - UK (£500), Europe (£700), rest of world (£1,000).

Apply before 1 February! Don't miss out - find out more 👉 https://bit.ly/3U0jk2E

Protecting our little ones is a top priority this New Year 🌟

Give children the best start by keeping vaccinations up to date. Childhood vaccinations protect against serious diseases and keep our communities safe 🤝

Read our guide to childhood vaccines: https://bit.ly/455bTui

📣 Excited about engaging the public in #immunology?

Apply for the BSI Communication & Engagement Grant! Up to £1,000 for projects that inspire, educate and build trust in science. #ScienceCommunication

Deadline: 1 February 2026! Apply here: https://bit.ly/3Y9j8gm

New year, new skills 🎉

Start 2026 by booking onto one of our training courses - flow cytometry, bioinformatics, foundations of immunology, immunology nursing or clinical immunology training days.

Invest in your immunology knowledge! Have a browse here: https://bit.ly/3RehpVN

Happy holidays from all of us! ❄️✨

Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!

Happy holidays from all of us! ❄️✨

Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!

Happy holidays from all of us! ❄️✨

Thank you to our authors, reviewers, and readers for another great year. We look forward to welcoming your submissions in the new year!

This going to be a great meeting

New Open Access study by Povoleri et al. shows anti-TNF therapy boosts IL-10 in CD4+ T cells, with MAF, PRDM1 & EOMES as key TF candidates.

🔗 https://bit.ly/44LZ7TR

Registrations are now open for 'Fuelling the immune response', the 4th UK immunometabolism meeting, led by the BSI Immunometabolism Affinity Group.

Join us in Newcastle on 16 and 17 April 2026 for cutting edge immune metabolism research #UKimmunomet26

Register here: https://bit.ly/493uE45

Natural killer cells are gaining momentum in cancer immunotherapy. This open-access review in Immunotherapy Advances explores how CAR-NK cells, NK engagers, cytokines and checkpoint inhibitors are being harnessed to boost anti-tumour immunity.

🔗 https://bit.ly/4j8dKEW

Take your R and omics skills to the next level! 🚀

Our advanced 'Further omics, statistics & clinical data in R' course starts 2 Feb 2026. Five Mondays online, packed with hands-on training for wet lab scientists.

Secure your spot now! https://bit.ly/47kXFaC